Market Intelligence, Clinical Progress, and High-Purity Reagents for CNS & Neurological Disorder Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for GABBR1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | GABBR1 ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1EU/µg. Sequence Verified. HEK293 Expressed. |
View GABBR1 Products |
| Obligate Partner | GABBR2 Full-Length Lentivirus Required heterodimer partner for functional GABA-B receptor assays. |
View GABBR2 Products |
| Gene Delivery | GABBR1 Promise-ORF Lentivirus Full-length ORF with CMV promoter; Puromycin selection marker for stable cell line generation. |
View GABBR1 Products |
| Benchmark Ab | Anti-GABBR1 (Functional Grade) Recombinant positive control for expression validation and IP. |
View GABBR1 Products |
| Validator | GABBR1 siRNA Set For knockdown verification and assay specificity controls. |
View GABBR1 Products |
| Related Target B | GABRA1 Crucial counter-screening target (GABA_A) to ensure drug selectivity. |
View GABRA1 Products |
| Related Target C | GAD1 (Glutamate Decarboxylase 1) Key GABA synthesis enzyme; upstream pathway component for circuit modulation studies. |
View GAD1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Complex Membrane Protein (GPCR) Conformation | Sequence-verified Lentivirus for Stable Cell Line generation. Cell-based assays are the only way to preserve conformation. |
| Heterodimer Functional Validation (GABBR1/GABBR2 co-expression required) | Matched Lentivirus pairs for GABBR1 and GABBR2 with consistent titers (>1×10^8 TU/ml); sequence-verified full-length ORFs preserve native Venus Flytrap (VFT) domain conformation. |
| Allosteric Modulator Binding Site Access | HEK293-expressed full-length receptors in native membrane context (Lentivirus-transduced stable lines) for physiologically relevant 7-TM topology. |
| Cross-species Translation (Cyno/Mouse/Rat) | Human/Mouse/Rat/Cyno ortholog proteins available with >95% sequence coverage; endotoxin-controlled for in vivo pharmacokinetic studies. |
| Class C GPCR Selectivity (mGluR off-target screening) | Homolog panel proteins (mGluR1-8) strictly verified by mass spectrometry for cross-reactivity assessment. |
| Lack of Reliable Controls for Flow Cytometry | Recombinant positive control benchmark antibodies (biosimilars) included. |
| False Positives in Signal Transduction Assays | Validated siRNA included for target-specificity verification; scramble controls provided. |
Live GABBR1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for GABBR1 therapeutics is intensifying, with major players shifting focus from traditional orthosteric agonists (like baclofen) to Positive Allosteric Modulators (PAMs) and biased ligands. As first-generation therapies for spasticity and muscle relaxation face limitations due to tolerance and sedation, the next wave of R&D is targeting localized receptor modulation, heterodimer-selective modulators that dissociate analgesic effects from sedative side effects through Gi/o-biased signaling. Key indications include neuropathic pain, substance abuse disorders, treatment-resistant depression, and Fragile X syndrome.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule PAMs | Addex Therapeutics, Novartis, Astralis Therapeutics | Substance Use Disorder, Neuropathic Pain, Addiction, Chronic Pain | Allosteric Potentiation (Need Lentivirus for Co-expression models & BRET assays) |
| Small Molecule Agonists | Various Generics, Indivior | Spasticity, Alcohol Use Disorder | Receptor Activation (Need Sequence Verified GPCR Cell Lines) |
| Biased Orthosteric Ligands | Eli Lilly, Lexicon Pharmaceuticals | Fragile X Syndrome, Epilepsy | β-arrestin vs Gi/o Pathway Bias Detection (Need full-length receptor in native membrane) |
| Subunit-Selective Modulators | Academic Consortia, Biotech | GERD, Sphincter Disorders | Homodimer vs Heterodimer Discrimination (Need GABBR1-specific binding assays without GABBR2) |
| Emerging Biologics | Early-stage Biotech | Refractory CNS Conditions | Binding Specificity (Need High-Purity GABBR1 ECD-Fc) |